Memphis, TN – October 26, 2023 – In a groundbreaking revelation poised to significantly reshape the landscape of long-term care for childhood cancer survivors, scientists at St. Jude Children’s Research Hospital have published a landmark study demonstrating that genetic predisposition, alongside life-saving cancer treatments, plays a far more substantial role in the risk of secondary cancers than previously understood. This pivotal research, appearing today in The Lancet Oncology, is the first to quantitatively attribute the proportional contributions of various factors to this critical health challenge, which remains the leading cause of mortality for individuals who have overcome childhood cancer.
The findings underscore a crucial message for physicians: care strategies for adult survivors of pediatric malignancies must evolve to incorporate a deeper understanding of their inherent genetic makeup, not just their treatment history. By meticulously analyzing data from two of the world’s most extensive childhood cancer survivor cohorts – the St. Jude Lifetime Cohort Study (St. Jude LIFE) and the Childhood Cancer Survivor Study (CCSS) – researchers have provided an unprecedented, population-level view of the complex interplay between treatment exposures, genetic vulnerabilities, and lifestyle choices in determining future cancer risk.
"We found the burden of second cancer in survivors of childhood cancer is largely contributed by pediatric treatment exposures and genetic predisposition," stated Dr. Yadav Sapkota, corresponding author and a distinguished researcher in the St. Jude Department of Epidemiology and Cancer Control. "We’ve known treatment exposures and genetics were associated with second cancer risk, but this is the first time we’ve been able to attribute the proportion of their contributions to that risk at the population level." This quantification marks a significant leap forward, providing a clearer roadmap for prevention, early detection, and personalized management.
Unraveling the Chronology of Discovery
The Enduring Challenge of Secondary Cancers
The journey to this groundbreaking discovery is rooted in decades of remarkable progress in pediatric oncology. In the latter half of the 20th century, advancements in chemotherapy, radiation therapy, and surgical techniques transformed childhood cancer from a uniformly fatal diagnosis into one with increasingly high survival rates. Today, more than 80% of children diagnosed with cancer will become long-term survivors, a testament to the relentless efforts of researchers and clinicians worldwide. However, this triumph has brought with it an emerging, complex challenge: the late effects of cancer treatment. As these survivors live longer, they face a heightened risk of various health complications, including cardiovascular disease, endocrine disorders, neurocognitive deficits, and critically, the development of secondary primary cancers.
Secondary cancers represent a particularly insidious threat. Unlike recurrence of the original cancer, these are new, distinct malignancies that arise often years or even decades after the successful treatment of the initial childhood cancer. For many long-term survivors, secondary cancers have tragically superseded the original disease as the primary cause of mortality. Historically, medical understanding and clinical guidelines for mitigating this risk have primarily focused on the known carcinogenic effects of specific treatments, such as certain types of radiation and chemotherapy. While invaluable, this approach has often treated these factors in isolation, leaving a critical gap in our understanding of their relative impact and the potential influence of other, less tangible elements.
Bridging a Critical Knowledge Gap
Previous scientific endeavors had indeed illuminated associations between particular treatment exposures, certain genetic predispositions, and even lifestyle factors with an increased risk of secondary cancers. However, these studies typically examined each factor independently, making it difficult to ascertain their comparative importance within the broader survivor population. The scientific community lacked a comprehensive, population-level analysis that could quantitatively dissect and attribute the proportional contribution of each element to the overall risk. This knowledge gap hindered the development of truly personalized risk assessment models and targeted prevention strategies.
Recognizing this critical need, scientists at St. Jude Children’s Research Hospital embarked on an ambitious project designed to address this deficit. Their strategy leveraged the unparalleled resources of two flagship studies housed at St. Jude: the St. Jude Lifetime Cohort Study (St. Jude LIFE) and the Childhood Cancer Survivor Study (CCSS). These cohorts represent the largest collection of childhood cancer survivor data in North America, providing an extraordinary opportunity for in-depth analysis.
"This kind of high-impact discovery is only possible in the CCSS and SJLIFE cohorts, that in combination, have more than 12,000 survivors with genetic sequencing," emphasized Dr. Greg Armstrong, co-author and Chair of the St. Jude Department of Epidemiology and Cancer Control. His statement underscores the sheer scale and depth of the data, which includes comprehensive treatment histories, detailed long-term health outcomes, extensive genetic information, and self-reported lifestyle factors, all meticulously collected over many years. This unique confluence of rich data made it possible for the St. Jude team to perform the nuanced, multi-factorial analysis required to disentangle the complex web of risk factors.
Methodological Rigor: A Deep Dive into Data
To address the knowledge gap, the St. Jude scientists meticulously compared data from over 10,000 survivors across the St. Jude LIFE and CCSS cohorts. The vastness and granularity of this dataset were critical. For each survivor, researchers had access to a wealth of information:
- Detailed Treatment Exposures: Precise records of chemotherapy agents received, cumulative doses, and radiation fields and dosages.
- Long-term Outcomes: Documented occurrences (or absence) of secondary cancers, including type, age at diagnosis, and treatment.
- Genetic Information: Comprehensive genetic sequencing data, including hundreds of common genetic variants previously linked to cancer in the general population (used to construct polygenic risk scores) and an examination of rare genetic variants.
- Lifestyle Factors: Data on diet, physical activity, smoking status, alcohol consumption, and other behaviors known to influence cancer risk.
This holistic approach allowed the researchers to move beyond simple associations and employ sophisticated statistical models to evaluate the independent and combined contributions of these diverse factors to the occurrence of secondary cancers. By doing so, they could attribute a specific percentage of the overall risk to each major category, providing the first quantitative partitioning of secondary cancer etiology at a population level.
Supporting Data: Quantifying the Risk Landscape
Radiation’s Enduring Legacy
The study’s findings reinforced the long-established understanding of radiation therapy as a significant contributor to secondary cancer risk. Radiation exposure emerged as the most potent single factor, accounting for approximately 40% or more of the subsequent cancer risk. This aligns with decades of prior research that has meticulously documented the long-term adverse effects of radiation, which, while life-saving for the primary cancer, can induce DNA damage and promote carcinogenesis in irradiated tissues.
The acknowledgment of radiation’s profound impact has already driven substantial shifts in modern pediatric oncology. Contemporary treatment protocols often involve lowered radiation doses, more targeted delivery techniques (such as proton therapy), or, where other effective treatments exist, the complete removal of radiation from the treatment regimen. The current study provides robust, population-level data that further validates these ongoing efforts to minimize radiation exposure and underscores the critical importance of continued vigilance and innovation in this area.
The Nuance of Chemotherapy and the Emergence of Genetics
While radiation’s impact was clear, the study unveiled more complex and nuanced relationships for chemotherapy and, notably, genetic predisposition. The contribution of chemotherapy to subsequent cancer risk varied significantly depending on the type of secondary cancer, ranging from 8% to 35%. This variability reflects the diverse mechanisms of action of different chemotherapeutic agents and their varying propensities to induce secondary malignancies. While the potential late effects of chemotherapy have been well-described, the proportional contribution of genetic predisposition to secondary cancer risk in survivors had been less clearly defined and often underestimated.
To better understand this genetic component, the researchers delved into the genetic profiles of the survivors. They examined hundreds of common genetic variants previously associated with cancer development in the general population. These variants were aggregated into what is known as a polygenic risk score (PRS), a statistical tool that estimates an individual’s genetic susceptibility to a particular disease based on the combined effect of many small genetic variations. In addition to the PRS, they also investigated the role of some rare genetic variants with known cancer associations.
The polygenic risk score approach proved highly informative, revealing that depending on the specific type of secondary cancer, genetic predisposition contributed significantly, accounting for 5% to 37% of the risk. This wide range highlights the heterogeneity of secondary cancers and the distinct genetic underpinnings that may drive different tumor types.
Dr. Yutaka Yasui, a co-author from the St. Jude Department of Epidemiology and Cancer Control, provided crucial context regarding the utility of PRS: "Polygenic risk scores are developed for all kinds of diseases for personalized medicine, but generally with precision below what is required for clinical utility in the general population. Among survivors of childhood cancer and for estimating their risk of certain types of subsequent cancer, however, they may provide useful information in conjunction with therapy exposures." This statement emphasizes that while PRS might have limitations in general population screening, its predictive power becomes particularly valuable when integrated with known treatment exposures in a high-risk cohort like childhood cancer survivors.
Shifting Paradigms: Genetics vs. Chemotherapy
Perhaps one of the most striking and paradigm-shifting findings of the study was the revelation regarding the relative importance of genetics compared to chemotherapy. "Our findings showed that genetics can be equally or more important than chemotherapy in some second cancers, which is counter to conventional wisdom in the field," Dr. Sapkota remarked. This challenges a long-held clinical perspective that predominantly emphasized treatment exposures as the paramount drivers of secondary cancer risk.
This finding suggests that for certain types of secondary cancers, a survivor’s inherent genetic susceptibility might be a stronger determinant of risk than the specific chemotherapy agents they received. For instance, a survivor with a high polygenic risk score for breast cancer might face a greater lifetime risk of developing a secondary breast cancer than another survivor who received a particularly aggressive chemotherapy regimen but possesses a lower genetic predisposition. This recalibration of risk factors necessitates a fundamental re-evaluation of how risk stratification and screening protocols are designed for this vulnerable population.
Lifestyle Factors: A Developing Story
In contrast to radiation, chemotherapy, and genetics, lifestyle factors—such as diet, exercise, and smoking—appeared to contribute much less to secondary cancer risk in this study, accounting for a comparatively small 1% to 6% of the overall risk. This finding might seem counterintuitive given the well-documented impact of lifestyle on cancer risk in the general population.
However, the researchers provided an important caveat: the majority of survivors included in this study were primarily in their 20s and 30s. At this relatively young age, the cumulative effects of lifestyle choices on cancer development may not yet have had sufficient time to manifest. Many lifestyle-related cancers typically develop later in life, after decades of exposure or unhealthy habits.
"We know healthy lifestyle choices are important for survivors," Dr. Sapkota clarified. "In this study, we focused only on the risk of second cancers, which may not be strongly impacted by lifestyle at this young age. However, other research has shown the benefits of healthy choices on other late effects, such as protecting cardiac wellbeing, so it is still important for clinicians to encourage—and patients to seek—a healthy lifestyle." This underscores that while lifestyle’s direct contribution to secondary cancer risk might be delayed, its overall importance for long-term health and prevention of other late effects remains undeniable. Future studies following these cohorts into older age will be crucial for a more complete understanding of lifestyle’s long-term impact on secondary cancer risk.
Official Responses and Expert Commentary
St. Jude’s Vision for Survivor Care
The publication of this study is a testament to St. Jude Children’s Research Hospital’s unwavering commitment to not only curing childhood cancer but also ensuring the highest possible quality of life for survivors throughout their lifespan. The institution has long been a pioneer in establishing comprehensive follow-up clinics and conducting extensive research into the late effects of cancer treatment. This new research, led by its own epidemiology and cancer control department, directly informs and advances St. Jude’s vision for holistic, survivor-centric care.
The insights provided by Drs. Sapkota, Armstrong, and Yasui reflect the institution’s official stance: that a deeper, more personalized understanding of risk factors is essential for optimizing long-term health outcomes. By providing the quantitative data on the contributions of genetics, St. Jude is advocating for a paradigm shift that integrates cutting-edge genomic information into routine clinical practice for survivors. This commitment extends beyond research, aiming to translate these findings into actionable clinical guidelines that will benefit survivors globally.
Broader Medical Community Reaction
While external expert commentary was not provided in the original release, the significance of this study is expected to resonate widely within the medical and scientific communities. Oncologists, pediatricians, primary care physicians, and genetic counselors who care for childhood cancer survivors are likely to view these findings as a critical advancement. The clear quantification of risk factors provides a robust evidence base for discussions with patients and families about individualized risk profiles.
The study will likely spark further research into specific genetic variants and their interactions with particular treatments, as well as the long-term impact of lifestyle factors in older survivor cohorts. It also strengthens the argument for integrating genetic counseling and advanced genetic testing into the standard of care for long-term survivors, moving beyond a purely treatment-centric view of risk. Professional organizations dedicated to cancer survivorship are expected to review and potentially update their guidelines based on this compelling new evidence.
The Role of Collaborative Research
The success of this study underscores the profound importance of large-scale, collaborative research initiatives. The ability to combine and analyze data from the St. Jude LIFE and CCSS cohorts, representing thousands of survivors across multiple institutions and decades of follow-up, was instrumental in achieving these robust and generalizable findings. The extensive list of authors from various leading institutions – including the University of Alberta, University of Minnesota, Baylor College of Medicine, University of Texas MD Anderson Cancer Center, and University of Alabama at Birmingham – highlights the power of multidisciplinary teamwork in addressing complex public health challenges. This collaborative spirit is vital for pooling resources, expertise, and diverse patient populations, ultimately leading to discoveries that would be impossible for any single institution to achieve alone.
Implications: Reshaping the Future of Survivor Care
Towards Personalized Risk Assessment and Screening
The most immediate and profound implication of this research lies in its potential to revolutionize personalized risk assessment and screening strategies for childhood cancer survivors. "Historically, we have paid attention to survivors’ treatment exposures when determining second cancer risk," Dr. Sapkota noted. "Our study suggests that we need to better account for genetic predisposition in this population."
This means moving towards a more sophisticated, multi-factorial risk model that incorporates not only the type and intensity of past treatments (especially radiation and specific chemotherapies) but also a survivor’s unique genetic profile, including their polygenic risk score. Survivors identified with a strong genetic predisposition for specific secondary cancers could then be candidates for more regular and intense surveillance programs. For instance, a survivor with a high genetic risk for breast cancer might begin mammograms or MRI screenings earlier than current guidelines suggest, or undergo them more frequently. Similarly, those with elevated genetic risk for colorectal cancer might require earlier or more frequent colonoscopies.
Empowering survivors with this knowledge is also a critical outcome. Armed with a comprehensive understanding of their unique combination of treatment-related, genetic, and emerging lifestyle risk factors, survivors can become more active participants in their own healthcare. They can better advocate to their health care providers about the need for specific, tailored screenings and preventive measures, fostering a more proactive and collaborative approach to long-term care.
Informing Future Treatment Protocols
Beyond individual patient care, the findings carry significant implications for the future design of primary childhood cancer treatment protocols. As researchers continue to refine their understanding of how specific treatments interact with genetic predispositions, there may be opportunities to further tailor initial therapies. For example, if a child is found to have a high genetic risk for a particular secondary cancer, clinicians might explore alternative, less carcinogenic treatment options for their primary cancer, if equally effective, to minimize long-term risk. This would involve a delicate balance between maximizing the cure rate for the initial cancer and mitigating the potential for late effects, striving for the optimal long-term outcome.
The study further reinforces the ongoing efforts to minimize radiation exposure in pediatric oncology. The robust quantification of radiation’s contribution to secondary cancer risk provides additional impetus for the continued development and adoption of highly targeted radiation techniques and non-radiation alternatives wherever feasible.
A Call for Continued Research
Despite its groundbreaking nature, this study also highlights areas for continued research. The precise mechanisms by which specific genetic variants interact with various treatment exposures warrant further investigation. Long-term follow-up of these cohorts into older age will be crucial to fully understand the delayed impact of lifestyle factors on secondary cancer risk. Additionally, research into novel prevention strategies, such as targeted chemoprevention for high-risk individuals, could emerge from these insights.
The ultimate goal of this and ongoing research at St. Jude and other institutions remains profoundly human: to extend and improve the quality of life for childhood cancer survivors. "Second cancers remain the leading cause of mortality for childhood cancer survivors," Dr. Sapkota reiterated. "Now that we have quantified the contributions of treatment, genetics and lifestyle to the risk of secondary disease, we have a better understanding of where to focus efforts to prevent, detect and treat these cancers, and hopefully extend these survivors’ lives." This study serves as a powerful beacon, guiding the way toward a future where the triumph over childhood cancer is truly a victory for a long, healthy life.
Acknowledgements
The study’s first author is Achal Neupane, of St. Jude. The extensive list of co-authors includes Siddhant Taneja, Jennifer French, Matthew Ehrhardt, Tara Brinkman, Rachel Webster, Jun Yang, Kirsten Ness, Melissa Hudson, Gregory Armstrong, Leslie Robison and Yutaka Yasui from St. Jude; Qi Liu from the University of Alberta; Cindy Im, Lucie Turcotte and Joseph Neglia from the University of Minnesota; Monica Gramatges from Baylor College of Medicine; Rebecca Howell from the University of Texas MD Anderson Cancer Center and Smita Bhatia from the University of Alabama at Birmingham.
This critical research was made possible through generous support from grants by the National Cancer Institute (R01HL173881, R01CA216354, R21CA261833, U24CA55727, U01CA195547 and CA21765) and ALSAC, the fundraising and awareness organization of St. Jude Children’s Research Hospital.
About the Author
